Literature DB >> 2055811

Quinolone resistance in campylobacter isolated from man and poultry following the introduction of fluoroquinolones in veterinary medicine.

H P Endtz1, G J Ruijs, B van Klingeren, W H Jansen, T van der Reyden, R P Mouton.   

Abstract

Eight hundred and eighty-three strains of Campylobacter spp. isolated between 1982 and 1989 from human stools and poultry products were screened for quinolone resistance. In this period the prevalence of resistant strains isolated from poultry products increased from 0% to 14%. During the same period the prevalence in man increased from 0% to 11%. The emergence of quinolone resistance has implications for the identification of campylobacter up to species level: the susceptibility for nalidixic acid can no longer be used as a criterion for identification in the laboratory. The rapid emergence of resistant campylobacter may also have important implications for the treatment and prophylaxis of diarrhoeal disease. The increase of quinolone resistance coincides with the increasing use of fluoroquinolones in human and veterinary medicine. Extensive use of enrofloxacin in poultry and the almost exclusive transmission route of campylobacter from chicken to man, in The Netherlands, suggests that the resistance observed is mainly due to the use of enrofloxacin in the poultry industry.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2055811     DOI: 10.1093/jac/27.2.199

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  104 in total

1.  Genotypic analysis of Escherichia coli strains from poultry carcasses and their susceptibilities to antimicrobial agents.

Authors:  I Geornaras; J W Hastings; A von Holy
Journal:  Appl Environ Microbiol       Date:  2001-04       Impact factor: 4.792

Review 2.  Antibiotic resistance: a current perspective.

Authors:  K F Barker
Journal:  Br J Clin Pharmacol       Date:  1999-08       Impact factor: 4.335

3.  Impact of Antibiotic Resistance on the Treatment of Gram-negative Sepsis.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-10       Impact factor: 3.725

4.  Susceptibilities of Campylobacter jejuni isolates from Germany to ciprofloxacin, moxifloxacin, erythromycin, clindamycin, and tetracycline.

Authors:  Jutta Wagner; Miriam Jabbusch; Martin Eisenblätter; Helmut Hahn; Constanze Wendt; Ralf Ignatius
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

5.  In vivo selection of Campylobacter isolates with high levels of fluoroquinolone resistance associated with gyrA mutations and the function of the CmeABC efflux pump.

Authors:  Naidan Luo; Orhan Sahin; Jun Lin; Linda O Michel; Qijing Zhang
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

6.  Antibiotic resistance in Campylobacter strains isolated from animals, foods, and humans in Spain in 1997-1998.

Authors:  Y Sáenz; M Zarazaga; M Lantero; M J Gastanares; F Baquero; C Torres
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

7.  Temporal prevalence of antimicrobial resistance in Campylobacter spp. from beef cattle in Alberta feedlots.

Authors:  G D Inglis; D W Morck; T A McAllister; T Entz; M E Olson; L J Yanke; R R Read
Journal:  Appl Environ Microbiol       Date:  2006-06       Impact factor: 4.792

8.  PCR-restriction fragment length polymorphism assay for detection of gyrA mutations associated with fluoroquinolone resistance in Campylobacter coli.

Authors:  Rodrigo Alonso; Estibaliz Mateo; Cecilia Girbau; Estibaliz Churruca; Irati Martinez; Aurora Fernández-Astorga
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

Review 9.  The epidemiology of bacterial resistance to quinolones.

Authors:  J F Acar; T F O'Brien; F W Goldstein; R N Jones
Journal:  Drugs       Date:  1993       Impact factor: 9.546

10.  Acute bacterial diarrhoea in the emergency room: therapeutic implications of stool culture results.

Authors:  N Kaminski; V Bogomolski; R Stalnikowicz
Journal:  J Accid Emerg Med       Date:  1994-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.